Treatment of Acne and Other Diseases
OwnerMorten Sloth Weidnerinventor
Life of this patent
Estimating the term…
Abstract
The invention relates to compounds for the treatment of dermatological diseases where inflammation, matrix metalloproteinases (MMPs) and peroxisome proliferator-activated receptors (PPARs) play a role in mediating the disease, such as the treatment of acne with Pemirolast or a closely related compound thereof.
Claims11
A method for treating a disease characterised by the presence of inflammation together with activity of matrix metalloproteinases and/or peroxisome proliferator-activated receptors, which disease is selected from the group consisting of acne, acne scarring, psoriasis, chronic ulcers, scars, burns, skin cancer, skin ageing, rosacea, seborrhea and seborrheic dermatitis, wherein said method comprises administering to a mammal a therapeutically effective amount of a medicament that contains Pemirolast or a closely related compound thereof or a pharmaceutically salt thereof, wherein the closely related compound thereof is defined by formula II,
- wherein R1 and R2 each independently designate radicals selected from the group consisting of hydrido (H), optionally substituted C1-6-alkyl, C4-6-cycloalkyl, C2-6-alkenyl, C2-6-alkynyl, C1-6-alkoxyl, phenyl, C7-14 alkaryl, C7-14 alkheterocyclyl, carboxyl (COOH), carboxyl derivative (COOR′), cyano (CN), CF3, halogen (Br, Cl, Fl, I), hydroxy (OH), hydroxy derivative (OR′), primary amino (NH2), secondary amino (NHR′), tertiary amino (NR′R″), carboxy (CO), carboxy derivative (CO—R′), and wherein R′ and R″ independently defines a radical selected from C1-6-alkyl, C4-6-cycloalkyl, C2-6-alkenyl, C2-6-alkynyl, C1-6-alkoxyl, phenyl, C7-14 alkaryl and C7-14 alkheterocyclyl;
- and wherein R1 and R2 may be located at any of positions 6, 7, 8 or 9 of the pyrido[1,2-a]pyrimidine ring system.
A topically administrable pharmaceutical composition comprising as therapeutically active ingredient Pemirolast or a closely related compound thereof or a pharmaceutically acceptable salt thereof in an amount of at least 0.1% by weight, and further comprising one or more dermatologically acceptable excipients or carriers.
Dependencies are inferred from the claim text.